Processing...
All Trials
Search
Search
There are 1652 active trials in our database.
Click on a trial to see more information.
1652 trials meet filter criteria.
Sort by:
TrialFetch AI summary: For men with PSMA-expressing metastatic castration-resistant prostate cancer with documented progression, at least one measurable metastatic lesion, ongoing castration (orchiectomy or ADT), and prior exposure to at least one androgen receptor pathway inhibitor. Participants receive single-agent TD001, a PSMA-targeted antibody–drug conjugate that binds PSMA and delivers an internalized exatecan (topoisomerase I inhibitor) cytotoxic payload, with dose-escalation and schedule exploration to identify a recommended dosing regimen.
ClinicalTrials.gov ID: NCT07258407
TrialFetch AI summary: Enrolls adults with metastatic castration-resistant prostate adenocarcinoma (ECOG 0–1) progressing on androgen deprivation therapy after at least one prior androgen receptor pathway inhibitor and 1–2 prior taxane chemotherapy regimens, excluding small cell/neuroendocrine histology and prior AR degrader therapy. Single-arm dose-escalation/optimization study of GSK5471713 monotherapy (reported as an investigational androgen receptor degrader) to define safety/PK and look for early PSA and radiographic responses.
ClinicalTrials.gov ID: NCT07332455
TrialFetch AI summary: Adults with ECOG 0–1 and locally advanced unresectable or metastatic sarcoma (≤2 prior metastatic systemic lines) or selected epithelial solid tumors (≤3 prior lines) with RECIST-measurable disease and required pretreatment biopsy/archival tissue are treated with ZL-6201 monotherapy in 21-day cycles. ZL-6201 is a first-in-human LRRC15-targeting antibody–drug conjugate delivering an internalized camptothecin-derivative (topoisomerase I inhibitor) payload via a protease-cleavable linker.
ClinicalTrials.gov ID: NCT07374848
TrialFetch AI summary: For children and adults (age 1–75) with histologically confirmed osteosarcoma that is recurrent, refractory, or progressive with new/worsening measurable or evaluable disease (including FDG-PET–avid bone metastasis not in complete remission after upfront therapy), ECOG 0–2 (or Lansky/Karnofsky ≥60), adequate organ function, and able to undergo leukapheresis (prior anthracycline-based therapy generally required). Patients receive lymphodepleting fludarabine/cyclophosphamide followed by a single infusion of autologous FH-FOLR1 ST CAR T cells targeting folate receptor alpha (FOLR1/FRα) to activate T-cell cytotoxicity against FOLR1-expressing tumor cells.
ClinicalTrials.gov ID: NCT07227571
TrialFetch AI summary: For adolescents and adults (≥30 kg; ECOG 0–2/Lansky ≥50) with histologically confirmed relapsed/refractory osteosarcoma after ≥1 prior chemotherapy regimen and RECIST-measurable/evaluable disease (including FDG-PET–avid bone-only disease). Participants receive single-agent LNTH-2403, an LRRC15-targeted lutetium-177–labeled monoclonal antibody radiotherapeutic delivering beta radiation to LRRC15-expressing tumor/stroma, dosed about every 8 weeks with imaging-based biodistribution/dosimetry.
ClinicalTrials.gov ID: NCT07357519
TrialFetch AI summary: Adults with relapsed/refractory small cell lung cancer after at least one prior platinum-based regimen (and in settings where standard, progressed on/ineligible for/no access to prior anti–PD-(L)1 therapy), excluding untreated CNS metastases and active/suspected autoimmune disease. Participants receive the investigational agent BMS-986525 (mechanism/target not publicly disclosed) as monotherapy or combined with nivolumab (PD-1 inhibitor), with dose-escalation and expansion cohorts assessing safety, PK, and preliminary activity.
ClinicalTrials.gov ID: NCT07325136
TrialFetch AI summary: This trial involves adults with unresectable locally advanced or metastatic NSCLC harboring active EGFR mutations, including C797S, who have progressed on osimertinib or another third-generation EGFR-TKI, receiving the investigational fourth-generation EGFR tyrosine kinase inhibitor H002 to assess its safety and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05519293
TrialFetch AI summary: The trial involves patients who are postmenopausal women with relapsed locally advanced or metastatic AR+/HER2-/ER+ breast cancer, focusing on the safety and efficacy of EP0062 (vosilasarm), a selective androgen receptor modulator. Participants must have previously treated, inactive cancer and meet specific cardiac and medication criteria.
ClinicalTrials.gov ID: NCT05573126
TrialFetch AI summary: The trial investigates the use of AG01, an anti-progranulin/GP88 monoclonal antibody, in patients with relapsed or refractory advanced solid tumors, including triple negative breast cancer, hormone-resistant breast cancer, non-small cell lung cancer, and mesothelioma, who have no remaining effective treatment options. AG01 is administered biweekly to evaluate its safety, tolerability, and preliminary anti-tumor activity.
ClinicalTrials.gov ID: NCT05627960
TrialFetch AI summary: This trial involves adult patients with refractory solid tumors unresponsive or declining standard treatments, evaluating the PCNA inhibitor AOH1996, which targets a cancer-specific variant to impair DNA replication and repair, dosed orally twice daily in a 28-day cycle.
ClinicalTrials.gov ID: NCT05227326